Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year / Simona Soverini; Alessandra Gnani; Sabrina Colarossi; Fausto Castagnetti; Francesca Palandri; Stefania Paolini; Cristina Papayannidis; Antonella Gozzini; Valeria Santini; Daniela Cilloni; Ester Orlandi; Serena Merante; Franca Radaelli; Michela Rondoni; Michele Malagola; Angela Poerio; Marilina Amabile; Ilaria Iacobucci; Gabriele Gugliotta; Gianantonio Rosti; Giovanni Martinelli; and Michele Baccarani. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 112:(2008), pp. 2118-2118. (Intervento presentato al convegno ASH tenutosi a san francisco nel 6-9 dicembre 2008).
Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.
SANTINI, VALERIA;
2008
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.